Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
2
40%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(1)

Detailed Status

unknown1
Withdrawn1
Active, not recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

unknown120%
withdrawn120%
active_not_recruiting120%
completed120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
terminatedphase_1

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

NCT03199040
unknown

Expanded Access Neoantigen Vaccine in Solid Tumors

NCT03914872
completedphase_1

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
withdrawnphase_2

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma

NCT03598816

Clinical Trials (5)

Showing 5 of 5 trials
NCT04397003Phase 2

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Active Not Recruiting
NCT03199040Phase 1

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Terminated
NCT03914872

Expanded Access Neoantigen Vaccine in Solid Tumors

Unknown
NCT03532217Phase 1

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Completed
NCT03598816Phase 2

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5